Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 6/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15173851 | 0.83 | RECQL (0.54) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL26542653 | 0.83 | KDM4E (0.56) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL20168111 | 0.81 | KDM4E (0.54) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL554373 | 0.81 | KDM4E (0.54) | KDM4EMAPK1SMN1; SMN2TSHRRECQL | |
| SCHEMBL15821360 | 0.81 | KDM4E (0.46) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL14967121 | 0.81 | KDM4E (0.46) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL4066614 | 0.75 | KDM4E (0.64) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL15819799 | 0.74 | ALDH1A1 (0.68) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL17382898 | 0.73 | KDM4E (0.46) | KDM4EMAPK1SMN1; SMN2TSHRPOLB | |
| SCHEMBL9084973 | 0.73 | ACHE (0.52) | KDM4EMAPK1SMN1; SMN2TSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49700-E1 | Substituted nitrogen containing compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | KDM4E 4071/4885MAPK1 1161/4885SMN1; SMN2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.